The influence of apolipoprotein E on the interactions between normal human very low density lipoproteins and U937 human macrophages: Heterogeneity among persons

Vascular Medicine

Volumn 1, Issue 1, 1996, Pages 9-18

  Sacks, Frank M ^a,b   Krukonis, Gregory P ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

apolipoprotein E; cell binding; macrophages; monocytes; U937 cells; VLDL

Indexed keywords

APOLIPOPROTEIN E; VERY LOW DENSITY LIPOPROTEIN; CHOLESTEROL; CHYLOMICRON; LIPOPROTEIN; LIPOPROTEIN LIPASE; LOW DENSITY LIPOPROTEIN RECEPTOR; MONOCLONAL ANTIBODY; TRIACYLGLYCEROL;

ADULT; ARTICLE; ATHEROSCLEROSIS; FEMALE; HUMAN; MACROPHAGE; MALE; MONOCYTE; NORMAL HUMAN; PRIORITY JOURNAL; ACCELERATION; AFFINITY CHROMATOGRAPHY; BINDING AFFINITY; BLOOD SAMPLING; CELL INTERACTION; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DECELERATION; GEL PERMEATION CHROMATOGRAPHY; ISOELECTRIC FOCUSING; LIPOLYSIS; MACROPHAGE MIGRATION; PRESCHOOL CHILD; PROTEIN BINDING; PROTEIN TRANSPORT; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0029994681     PISSN: 1358863X     EISSN: None     Source Type: Journal    
DOI: 10.1177/1358863X9600100103     Document Type: Article

References (65)

1. Grundy SM. The multifactorial etiology of hypercholesterolemia. Implications for prevention of coronary heart disease. Arterioscler Thromb 1991; 11: 1619-35.
2. Marcel YL, Hogue M, Weech PK, Davignon J, Milne RW. Expression of apolipoprotein B epitopes in lipoproteins. Relationship to conformation and function. Arteriosclerosis 1988; 8: 832-44.
3. Bradley WA, Hwang S-LC, Karlin JB et al. Low-density lipoprotein receptor binding determinants switch from apolipoprotein E to apolipoprotein B during conversion of hypertriglyceridemic very-low-density lipoprotein to low-density lipoproteins. J Biol Chem 1984; 259: 14728-35.
4. Krul ES, Tikkanen, MJ, Cole TG, Davie JM, Schonfeld G. Roles of apolipoproteins B and E in the cellular binding of very low density lipoproteins. J Clin Invest 1985; 75: 361-69.
5. Hui DY, Innerarity TL, Milne RW, Marcel YL, Mahley RW. Binding of chylomicron remnants and β-very low density lipoproteins to hepatic and extrahepatic lipoprotein receptors: a process independent of apolipoprotein B-48. J Biol Chem 1984; 259: 15060-68.
6. Shore VG, Shore B. Heterogeneity of human plasma very low density lipoproteins. Separation of species differing in protein components. Biochemistry 1973; 12: 502-507.
7. Kane JP, Sata T, Hamilton RL, Havel RJ. Apoprotein composition of very low density lipoproteins of human serum. J Clin Invest 1975; 56: 1622-34.
8. Trezzi E, Calvi C, Roma P, Catapano AL. Subfractionation of human very low density lipoproteins by heparin-Sepharose chromatography. J Lipid Res 1983; 24: 790-95.
9. Shelburne FA, Quarfordt SH. The interaction of heparin with an apoprotein of human very low density lipoprotein. J Clin Invets 1977; 60: 944-50.
10. Fielding PE, Fielding CJ. An apo-E-free very low density lipoprotein enriched in phosphatidylethanolamine in human plasma. J Biol Chem 1986; 261: 5233-36.
11. Krul ES, Tikkanen, MK, Schonfeld G. Heterogeneity of apolipoprotein E epitope expression on human lipoproteins: importance for apolipoprotein E function. J Lipid Res 1988; 29: 1309-25.
12. Agnani G, Bard JM, Candelier L, Delattre S, Fruchart J-C, Clavey V. Interaction of LpB:E, LpB:C-III, and LpB:C-III:E lipoproteins with the low density lipoprotein receptor of HeLa cells. Arterioscler Thromb 1991; 11: 1021-29.
13. c. Proc Natl Acad Sci USA 1979; 76: 2311-15.
14. Funahashi T, Yokoyama S, Yamamoto A. Association of apolipoprotein E with the low density lipoprotein receptor: demonstration of its co-operativity on lipid microemulsion particles. J Biochem 1989; 105: 582-87.
15. Mims MP, Soma MR, Morrisett JD. Effect of particle size and temperature on the conformation and physiological behavior of apolipoprotein E bound to model lipoprotein particles. Biochemistry 1990; 29: 6639-47.
16. Chappell DA. High receptor binding affinity of lipoproteins in atypical dysbetalipoproteinemia (type III hyperlipoproteinemia). J Clin Invest 1989; 84: 1906-15.
17. Ishibashi S, Yamada N, Shimano H et al. Apolipoprotein E and lipoprotein lipase secreted from human monocyte-derived macrophages modulate very low density lipoprotein uptake. J Biol Chem 1990; 265: 3040-47.
18. Eisenberg S, Friedman G, Vogel T. Enhanced metabolism of normolipidemic human plasma very low density lipoprotein in cultured cells by exogenous apolipoprotein E-3. Arteriosclerosis 1988; 8: 480-87.
19. Bates SR, Coughlin BA, Mazzone T, Borensztajn J, Getz GS. Apoprotein E mediates the interaction of β-VLDL with macrophages. J Lipid Res 1987; 28: 787-97.
20. Mahley RW, Hui DY, Innerarity TL, Beisiegel U. Chylomicron remnant metabolism. Role of hepatic lipoprotein receptors in mediating uptake. Arteriosclerosis 1989; 9 (suppl I): I-14-I-18.
21. Jaeckle S, Brady SE, Havel RJ. Membrane binding sites for plasma lipoproteins on endosomes from rat liver. Proc Natl Acad Sci USA 1989; 86: 1880-84.
22. Kowal RC, Herz J, Goldstein JL, Esser V, Brown MS. Low density lipoprotein receptor-related protein mediates uptake of cholesteryl esters derived from apoprotein E-enriched lipoproteins. Proc Natl Acad Sci USA 1989; 86: 5810-14.
23. Arbeeny CM, Rifici VA. The uptake of chylomicron remnants and very low density lipoprotein remnants by the perfused rat liver. J Biol Chem 1984; 259: 9662-66.
24. Windler E, Chao Y-S, Havel RJ. Determinants of hepatic uptake of triglyceride-rich lipoproteins and their remnants in the rat. J Biol Chem 1980; 255: 5475-80.
25. Krempler F, Kostner GM, Friedl W, Paulweber B, Bauer H, Sandhofer F. Lipoprotein binding to cultured human hepatoma cells. J Clin Invest 1987; 80: 401-408.
26. Shelburne FA, Hanks J, Meyers W, Quarfordt SH. Effect of apoproteins on hepatic uptake of triglyceride emulsions in rat. J Clin Invest 1980; 65: 652-58.
27. Yamada N, Shames DM, Takahashi K, Havel RJ. Metabolism of apolipoprotein B-100 in large very low density lipoproteins of blood plasma. Kinetic studies in normal and Watanabe heritable hyperlipidemic rabbits. J Clin Invest 1988; 82: 2106-13.
28. Huff MW, Telford DE. Characterization and metabolic fate of two very-low-density lipoprotein subfractions separated by heparin-sepharose chromatography. Biochim Biophys Acta 1984; 796: 251-61.
29. Eaton RP, Allen RC, Schade DS. Overproduction of a kinetic subclass of VLDL-apoB, and direct catabolism of VLDL-apoB in human endogenous hypertriglyceridemia: an analytical model solution of tracer data. J Lipid Res 1983; 24: 1291-303.
30. Packard CJ, Munro A, Lorimer AR, Gotto AM, Shepherd J. Metabolism of apolipoprotein B in large triglyceride-rich very low density lipoproteins of normal and hypertriglyceridemic subjects. J Clin Invest 1984; 74: 2178-92.
31. Schaefer EJ, Gregg RE, Ghiselli G et al. Familial apolipoprotein E deficiency. J Clin Invest 1986; 78: 1206-19.
32. Gregg RE, Zech LA, Schaefer EJ, Brewer HB, Jr. Type III hyperlipoproteinemia: defective metabolism of an abnormal apolpoprotein E. Science 1981; 211: 584-86.
33. Huff MW, Evans AJ, Sawyez CG, Wolfe BM, Nestel PJ. Cholesterol accumulation in J774 macrophages induced by triglyceride-rich lipoproteins. Comparison of very low density lipoprotein from subjects with type III, IV, and V hyperlipoproteinemias. Arterioscler Thromb 1991; 11: 221-33.
34. Hui DY, Innerarity TL, Mahley RW. Defective hepatic lipoprotein receptor binding of β-very low density lipoproteins from type III hyperlipoproteinemic patients. J Biol Chem 1984; 259: 860-69.
35. Evans AJ, Sawyez CG, Wolfe BM, Connelly PW, Maguire GF, Huff MW. Evidence that cholesteryl ester and triglyceride accumulation in J774 macrophages induced by VLDL subfractions occurs by different mechanisms. J Lipid Res 1993; 34: 703-17.
36. Sacks FM, Breslow JL. Very low density lipoproteins stimulate cholesteryl ester formation in U937 macrophages. Heterogeneity and biologic variation among normal humans. Arteriosclerosis 1987; 7: 35-46.
37. Fielding PE, Ishikawa Y, Fielding CJ. Apolipoprotein E mediates binding of normal very low density lipoprotein to heparin but is not required for high affinity receptor binding. J Biol Chem 1989; 264: 12462-66.
38. Keidar S, Kaplan M, Rosenblat M, Brook GJ, Aviram M. Apolipoprotein E and lipoprotein lipase reduce macrophage degradation of oxidized VLDL but increase cellular degradation of native VLDL. Metabolism 1992; 41: 1185-92.
39. Wang-Iverson P, Ginsberg HN, Peteanu LA, Le N-A, Brown WV. Apo E-mediated uptake and degradation of normal very low density lipoproteins by human monocyte/macrophages: a saturable pathway distinct from the LDL receptor. Biochem Biophys Res Commun 1985; 126: 578-86.
40. Milne RW, Douste-Blazy Ph, Marcel YL. Characterization of monoclonal antibodies against human apolipoprotein E. J Clin Invest 1981; 68: 111-17.
41. Weisgraber KH, Innerarity TL, Harder KJ et al. The receptor-binding domain of human apolipoprotein E. Monoclonal antibody inhibition of binding. J Biol Chem 1983; 258: 12348-54.
42. Lindgren FT, Jensen LC, Hatch FT. The isolation and quantitative analysis of serum lipoproteins. In: Nelson GJ ed. Blood lipids and lipoproteins: quantitation, composition, and metabolism. New York: Wiley, 1972: 181-274.
43. Goldstein JL, Basu SK, Brown MS. Receptor-mediated endocytosis of low-density lipoprotein in cultured cells. Methods Enzymol 1983; 98: 241-60.
44. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951; 193: 265-75.
45. Sundstrom C, Nilsson K. Establishment and characterization of a human histiocytic lymphoma cell line (U-937). Int J Cancer 1976; 17: 565-77.
46. Zannis VI, McPherson J, Goldberger G, Karathanasis SK, Breslow JL. Synthesis, intracellular processing, and signal peptide of apolipoprotein E. J Biol Chem 1984; 259: 5495-99.
47. Moscicki RA, Amento EP, Krane SJ, Kurnick JT, Colvin RB. Modulation of surface antigens of a human monocyte cell line, U937, during incubation with T lymphocyte-conditioned medium: detection of T4 antigen and its presence on normal blood monocytes. J Immunol 1983; 131: 743-48.
48. Keidar S, Goldberg AC, Cook K, Bateman J, Schonfeld G. A high carbohydrate-fat free diet alters the proportion of heparin-bound VLDL in plasma and the expression of VLDL-apoB-100 epitopes. Metabolism 1990; 39: 281-88.
49. Nestel P, Tada N, Billington T, Huff M, Fidge N. Changes in very low density lipoproteins with cholesterol loading in man. Metabolism 1982; 31: 398-405.
50. Weisgraber KH, Rall SC, Mahley RW, Milne RW, Marcel YL, Sparrow JT. Human apolipoprotein E. Determination of the heparin binding sites of apolipoprotein E3. J Biol Chem 1986; 261: 2068-76.
51. Evans AJ, Huff MW, Wolfe BM. Accumulation of an apo-E-poor subfraction of very low density lipoprotein in hypertriglyceridemic men. J Lipid Res 1989; 30: 1691-701.
52. Leowsky J, James RW, Taton J, Pometta D. The influence of metabolic control on very low density lipoprotein composition in hypertriglyceridemic type II diabetics. A study using heparin-sepharose chromatography. Metabolism 1988; 37: 721-26.
53. Nestel P, Billington T, Tada N, Nugent P, Fidge N. Heterogeneity of very-low-density lipoprotein metabolism in hyperlipidemic subjects. Metabolism 1983; 32: 810-17.
54. Weisgraber KH, Rall SC. Human apolipoprotein B-100 heparin binding sites. J Biol Chem 1987; 262: 11097-103.
55. Granot E, Schwiegelshohn B, Tabas I et al. Effects of particle size on cell uptake of model triglyceride-rich particles with and without apoprotein E. Biochemistry 1994; 33: 15190-97.
56. Ishikawa Y, Fielding CJ, Fielding PE. A change in apolipoprotein B expression is required for the binding of apolipoprotein E to very low density lipoprotein. J Biol Chem 1988; 263: 2744-49.
57. Blum CB. Dynamics of apolipoprotein E metabolism in humans. J Lipid Res 1982; 23: 1308-16.
58. Catapano AL, Gianturco SH, Kinnunen PK, Eisenberg S, Gotto AM Jr, Smith LC. Suppression of 3-hydroxy-3-methylglutaryl-CoA reductase by low density lipoproteins produced in vitro by lipoprotein lipase action on nonsuppressive very low density lipoproteins. J Biol Chem 1979; 254: 1007-1009.
59. Schonfeld G, Patsch W, Pfleger B, Witztum JL, Weidman SW. Lipolysis produces changes in the immunoreactivity and cell reactivity of very low density lipoproteins. J Clin Invest 1979; 64: 1288-97.
60. Chappell DA. Pre-beta-very low density lipoproteins as precursors of beta-very low density lipoproteins. A model for the pathogenesis of familial dysbetalipoproteinemia (type III hyperlipoproteinemia). J Clin Invest 1988; 82: 628-39.
61. Rubinstein A, Gibson JC, Ginsberg HN, Brown WV. In vitro metabolism of apolipoprotein E. Biochim Biophys Acta 1986; 879: 355-61.
62. Gianturco SH, Brown FB, Gotto AM, Bradley WA. Receptor-mediated uptake of hypertriglyceridemic very low density lipoproteins by normal human fibroblasts. J Lipid Res 1982; 23: 984-93.
63. Schwiegelshohn B, Presley JF, Gorecki M et al. Effects of apoprotein E on intracellular metabolism of model triglyceride-rich particles are distinct from effects on cell particle uptake. J Biol Chem 1995; 270: 1761-69.
64. Gianturco SH, Lin AH-Y, Hwang S-LC et al. Distinct murine macrophage receptor pathway for human triglyceride-rich lipoproteins. J Clin Invest 1988; 82: 1633-43.
65. Kannel WB. Range of serum cholesterol values in the population developing coronary heart disease. Am J Cardiol 1995; 76: 69C-77C.